A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2018
At a glance
- Drugs E 6011 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 15 May 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2019.
- 15 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 07 Feb 2018 Status changed from recruiting to active, no longer recruiting.